Search
Enter keywords, a title or a report id number below.
Your Search for 'Immunogenicity to Biologics' returned 40 results - Page 1 of 2
Sort by
Sorted by
Rank
Top-Bottom
-
Next-Generation Protein and Peptide Therapeutics
Scripp Business Insights, Aug 2011 , Pages: 192Next-Generation Protein and Peptide Therapeutics The utility of mAb therapeutics is balanced by many drawbacks: they are expensive to produce, have poor tissue penetration, can only be used to target ... -
Conference: Cell Based Assays: Scientific Innovations & Market Analysis
Appel Consulting Ltd, Jun 2013 , Days: 2Head Biologics Novartis 12:00 Cellular systems to address the efficacy, selectivity and mechanism of action of kinase inhibitors - Cell based system for assessing the activity and selectivity of ... -
Biosimilars: Current Situation & Future Prospects, Worldwide
Just Pharma Reports, Mar 2012 , Pages: 135problems related to use of biosimilars Immunogenicity potential of selected biologics Frequency of antibody formation; biosimilars and reference products Sandoz’ principles for science-based biosimilar ... -
Biobetters: Major Players and Market Prospects (2nd edition)
FirstWord Publishing, Sep 2011 , Pages: 48immunogenicity as a defensive shield - Prediction is a risky game - Clinical trials as the current gold-standard for immunogenicity testing - Biobetters – the route to market - The full approval pathway beckons ... -
Biosimilars and Biobetters: Positioning for a New Market 2009
Select Biosciences Ltd, Jul 2009 , Pages: 275companies to enter the biologics market, a segment which is uniquely driven by unmet needs, commands premium prices, and continues to outperform the global pharma market. This new and timely report analyzes ... -
Anti-TNF Therapies in IBD: Opinion Leader Insight into Current & Future Treatment Practices
Sociable Pharma, Apr 2011 , Pages: 130begun to reshape the treatment landscape for inflammatory bowel disease. There are now well-established treatment strategies for biologics in both Crohn's disease and ulcerative colitis but it will be the ... -
Conference: 3rd Biosimilars Summit & Trade Exhibition - 2013 Innovations & Developments : A Decade at a Glance
Appel Consulting Ltd, Jun 2013 , Days: 23.7billion in 2015. With more than 30 branded biologics with sales of $51billion set to lose patent exclusivity. Between 2011 and 2015, it is forecast that “biosimilar monoclonal antibodies” and “second ... -
Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry
Woodhead Publishing Ltd, Sep 2012 , Pages: 640engineering. Introduction to biologics and monoclonal antibodies - Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins - Antibody structure–function relationships - Fundamental ... -
Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects
PharmaVision, Aug 2010 , Pages: 183remain to improve the cost-effective manufacture and production of biologics, and to enhance their delivery, pharmacokenetics and reduce immunogenicity. Despite these issues recent advances in mAbs and TPs ... -
Biosimilars and Biobetters: Positioning for a New Market
Biophoenix Limited, Jul 2009 , Pages: 275enter the biologics market, a segment which is uniquely driven by unmet needs, commands premium prices, and continues to outperform the global pharma market. This new and timely report analyzes the ... -
Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?
FirstWord Publishing, Nov 2011 , Pages: 47International - Andrew Teuten, Senior Partner, Sagittarius IP Key Quotes “The size of the global biologics market creates a massive opportunity for biosimilar developers to come in and take some of that market ... -
Biosimilars Update
FirstWord Publishing, Apr 2011requirements by the EMA, immunogenicity assessments, a guide to the FDA's position and a section on pharmacovigilance, the report is an accurate state-of-play on a dynamic and shifting industry. The reports ... -
PK Assays for Biotherapeutics - Part 1
Future Medicine Ltd, Mar 2011 , Pages: 96combination biologics: analytical challenges related to pharmacokinetic assays and interpretation of pharmacokinetic and immunogenicity results Lauren Stevenson, et al - Dual ligation hybridization assay for ... -
India Biosimilar Market Analysis
Kuick Research, Aug 2012 , Pages: 80serious health issues. One of the key challenges regarding biosimilar products is immunogenicity. Studies that compare innovator biologics and biosimilars often report differences in aggregate levels ... -
Next-Generation Biologics: Improving on Monoclonal Antibodies
Decision Resources, Inc, Dec 2007 , Pages: 35and Royalty Stacking Delivery Immunogenicity Industry Interest and Clinical Development Remaining Challenges for MAb Alternatives Appendix A. Types of Biologic Alternatives to Therapeutic ... -
Business Strategies for Different Types of Biogenerics
Decision Resources, Inc, Nov 2007 , Pages: 32nuances of specific biologics markets but also the long-term commitment they will be required to make when developing biogenerics and the significant capital investment that will be required to achieve ... -
The Biogenerics Market Outlook: An Analysis of Market Dynamics, Growth Drivers and Leading Players
Scripp Business Insights, Mar 2005companies will benefit from the advent of generic biologics and identifies the companies who have the most to lose by examining the risks associated with the leading biologic brands. By 2010, biologic ... -
Production of Therapeutic Glycoproteins - Patent and Technology Report - Key Players, Innovators and Industry Analysis
Dolcera, Nov 2011 , Pages: 78biotherapeutics is expected to open up, which is worth billions of dollars. Biosimilars or follow-on biologics of the original glycoprotein drugs has led to the marketing of ‘copies’ of these drugs, varying in ... -
Protein Drugs - Global Strategic Business Report
Global Industry Analysts, Inc, Aug 2010 , Pages: 524Protein drugs, also referred to as biologics, are pharmaceuticals based upon proteins. Advent of proteomics and high-throughput screening has helped expand the range of protein drugs available for disease ... -
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging Technologies and New Therapeutic Candidates
Scripp Business Insights, Mar 2010 , Pages: 392. Key findings from this report - Early challenges relating to immunogenicity, tissue penetration, administration and production of monoclonal antibodies are being addressed by myriad new technologies ...
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
